A5071798797- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Pancreatitis Pathology and Treatment
- Renal cell carcinoma treatment
- Advanced Radiotherapy Techniques
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neuroendocrine Tumor Research Advances
- Radiation Therapy and Dosimetry
- Gallbladder and Bile Duct Disorders
- Gastric Cancer Management and Outcomes
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Screening and Detection
- Advanced MRI Techniques and Applications
- Economic and Financial Impacts of Cancer
- Colorectal Cancer Surgical Treatments
- Medical Imaging Techniques and Applications
- Hepatocellular Carcinoma Treatment and Prognosis
- MRI in cancer diagnosis
- Nanoplatforms for cancer theranostics
- Lung Cancer Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Frailty in Older Adults
- Colorectal Cancer Treatments and Studies
- Health Systems, Economic Evaluations, Quality of Life
- Prostate Cancer Treatment and Research
St. Antonius Ziekenhuis
2017-2025
University Medical Center Utrecht
2016-2025
Utrecht University
2020-2025
Cancer Genomics Centre
2018-2025
Netherlands Comprehensive Cancer Organisation
2021-2025
Heidelberg University
2023-2024
University Hospital Heidelberg
2023-2024
Erasmus MC Cancer Institute
2023
Meander Medisch Centrum
2020-2021
Amsterdam UMC Location University of Amsterdam
2017
Objective: To establish an evidence-based cutoff and predictors for early recurrence in patients with resected locally advanced pancreatic cancer (LAPC). Background: It is unclear how many which develop after LAPC resection. Surgery these probably of little benefit. Methods: We analyzed all consecutive undergoing resection induction chemotherapy who were included prospective databases The Netherlands (2015–2019) the Johns Hopkins Hospital (2016–2018). optimal definition “early recurrence”...
Objective: To establish minimal and optimal lymphadenectomy thresholds for intraductal papillary mucinous neoplasm (IPMN)-derived pancreatic ductal adenocarcinoma (PDAC) evaluate their prognostic value. Background: Current guidelines recommend a minimum of 12-15 lymph nodes (LNs) in PDAC. This is largely based on intraepithelial neoplasia (PanIN)-derived PDAC, biologically distinct entity from IPMN-derived Methods: Multicenter retrospective study including consecutive patients undergoing...
Abstract Background Novel definitions suggest that resectability status for pancreatic ductal adenocarcinoma (PDAC) should be assessed beyond anatomical criteria, considering both biological and conditional factors. This has, however, yet to validated on a nationwide scale. study evaluated the prognostic value of factors staging patients with resectable PDAC. Patients Methods A observational cohort was performed, including all consecutive who underwent upfront resection National...
Abstract Background Disease recurrence remains one of the biggest concerns in patients after resection pancreatic ductal adenocarcinoma (PDAC). Despite (neo)adjuvant systemic therapy, most experience local and/or distant PDAC within 2 years. High-level evidence regarding benefits recurrence-focused surveillance is missing, and impact early detection treatment on survival quality life unknown. In European countries, follow-up surgery for currently lacking. Consequently, guidelines...
Objective: The aim of the study was to investigate prognostic factors in context neoadjuvant therapy (NAT) and develop tools that can allow for accurate personalized patient prognostication. Summary Background Data: NAT might impact ability well-established clinicopathological resected pancreatic ductal adenocarcinoma (PDAC). Methods: Patients after resection PDAC were identified from Dutch Pancreatic Cancer Group Recurrence Database institutional databases at NYU Langone Health Johns...
Introduction of online adaptive MR-guided radiotherapy enables stereotactic body radiation therapy (SBRT) upper abdominal tumors. This study aimed to evaluate the feasibility SBRT on a 1.5 T MR-linac in patients with unresectable malignancies.Patients treated at UMC Utrecht (April 2019 December 2020) were identified prospective 'Multi-OutcoMe EvaluatioN Therapy Using MR-linac' (MOMENTUM) study. Feasibility treatment was arbitrarily defined as an on-table time interval ≤60 min for >75%...
Whereas neoadjuvant chemo(radio)therapy is increasingly used in pancreatic cancer, it currently not recommended for other periampullary (non-pancreatic) cancers. This has important implications the relevance of preoperative diagnosis pancreatoduodenectomy. retrospective multicentre cohort study aimed to determine frequency clinically relevant misdiagnoses patients undergoing pancreatoduodenectomy or cancer.Data from all consecutive who underwent a between 2014 and 2018 were obtained...
Abstract Background The causal pathway between complications after pancreatic cancer resection and impaired long-term survival remains unknown. aim of this study was to investigate the impact on disease-free interval overall survival, with adjuvant chemotherapy as a mediator. Methods This observational included all patients undergoing in Netherlands (2014–2017). Clinical data were extracted from prospective Dutch Pancreatic Cancer Audit. Recurrence collected additionally. In mediation...
Background & AimsCytologic and histopathologic diagnosis of non-ductal pancreatic neoplasms can be challenging in daily clinical practice, whereas it is crucial for therapy prognosis. The cancer methylome successfully used as a diagnostic tool other entities. Here, we investigate if methylation profiling improve the work-up neoplasms.MethodsDNA data were obtained 301 primary tumors spanning 6 20 normal pancreas controls. Neural Network, Random Forest, extreme gradient boosting machine...
In 2018, the first online adaptive magnetic resonance (MR)-guided radiotherapy (MRgRT) system using a 1.5-T MR-equipped linear accelerator (1.5-T MR-Linac) was clinically introduced. This enables radiotherapy, in which radiation plan is adapted to size and shape changes of targets at each treatment session based on daily MR-visualized anatomy.
PURPOSE The benefit of adjuvant therapy for intraductal papillary mucinous neoplasm (IPMN)-derived pancreatic ductal adenocarcinoma (PDAC) remains unclear because severely limited evidence. Although biologically distinct entities, practices IPMN-derived PDAC are largely founded on intraepithelial neoplasia-derived PDAC. We aimed to evaluate the role chemotherapy in METHODS This international multicenter retrospective cohort study (2005-2018) was conceived at Verona Evidence-Based Medicine...
Intraductal papillary mucinous neoplasm (IPMN)-derived pancreatic cancer is typically managed like intraepithelial neoplasia (PanIN)-derived cancer. However, in IPMN-derived cancer, the role of chemotherapy remains controversial, particularly neoadjuvant setting (NAT). To evaluate Patients with treated either upfront surgery (US) or NAT were identified from eight international centers (2000-2023). Clinicopathologic data compared. Date first treatment was used for Kaplan-Meier and log-rank...